Chimeric antigen receptor T-cell therapy - Hebei Senlang Biotechnology

Drug Profile

Chimeric antigen receptor T-cell therapy - Hebei Senlang Biotechnology

Alternative Names: Autologous CAR-T - Hebei Senlang Biotechnology; CAR-T cell therapy - Hebei Senlang Biotechnology

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebei Senlang Biotechnology
  • Developer Hebei Medical University Fourth Hospital; Hebei Senlang Biotechnology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD antigen inhibitors; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 26 Apr 2017 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in China (Parenteral) (NCT03121625) (ChiCTR-ONC-17011212)
  • 21 Apr 2017 Hebei Senlang Biotechnology initiates enrolment in a clinical trial for Haematological malignancies (Second-line therapy or greater) in China (Parenteral) (ChiCTR-ONC-17011211)
  • 26 Dec 2016 Preclinical trials in Haematological malignancies in China (Parenteral) before December 2016 (NCT03121625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top